GHRP6

GHRP-6

A synthetic hexapeptide, His-D-Trp-Ala-Trp-D-Phe-Lys-NH2, and an agonist at the growth hormone secretagogue receptor type 1a. It differs from GHRP-2 at two positions and was the earlier of the two to be described.

No registered human study names GHRP-6 as an intervention. ClinicalTrials.gov holds no trial of it, so there is no trial evidence to read — a fact about the public record rather than proof the compound does nothing. No FDA-approved product contains GHRP-6. 134 papers naming it were published in the last ten years.

Collected 2026-08-02 from ClinicalTrials.gov and Drugs@FDA. Counts include only trials whose registered intervention names GHRP-6; the registry search is fuzzy, so every match is re-checked. None of this says whether GHRP-6 works or is safe.

FDA status

Research only

Human studies

0

Furthest phase

Papers, 10 yr

134

Readership

1,552

monthly average, Feb–Jul 2026

Tracking since 2026-07-29 · About this data

What has actually been tested in humans

X

No registered human study

0

Registered human studies

None

No FDA-approved product contains it

No study of GHRP-6 in humans is registered on ClinicalTrials.gov. That is a fact about the public record, not a statement that the compound does nothing — but it does mean there is no trial evidence to read, and anyone telling you otherwise should be asked for the registration number. The grade is mechanical: it is computed from the registry and the FDA record alone, and it grades how much is known, never whether a compound is good or safe. Collected 2026-08-02 from ClinicalTrials.gov and Drugs@FDA. Check the query.

What GHRP-6 is, and what it has been studied for

GHRP-6 is tracked here.

No registered trial names GHRP-6 as an intervention, so there is no condition it has been formally studied in. It does have a literature: 134 indexed papers name it in the last ten years. That work is laboratory and animal research, and a paper is not a trial.

Is anyone studying GHRP-6?

Papers published each year that name GHRP-6 in the title or abstract, with the clinical trials that started in the same year marked beneath. Ten calendar years.

0613192517181920212223242526
Vertical axis: papers published that year. Bar for 2026 is hatched because that year is still running.
Publications and trials naming GHRP-6, by year
YearPublicationsTrials startedComplete year
2017220Yes
2018200Yes
2019240Yes
2020160Yes
2021190Yes
2022130Yes
2023110Yes
2024100Yes
2025140Yes
202680No

134 papers between 2017 and 2026. A paper counts when “GHRP-6” appears in its title or abstract — phrase-matched, so a paper mentioning the words separately is not counted. The total is a single query over the whole window, which is why it does not equal the bars added together: PubMed files a paper under both its electronic and its print publication date, so one paper can appear in two years. Publication volume measures scientific attention, not whether a compound works: a well-studied compound can be well-studied and ineffective. Sources: PubMed and ClinicalTrials.gov · collected 2026-08-02.

Published research on GHRP-6

134 indexed papers name GHRP-6 in their title or abstract. These are the 8 PubMed ranks most relevant. Listing a paper is not a judgement about it, and none of these is summarised here — follow the link and read what it says.

  1. N-aminoimidazolidin-2-one peptidomimetics

    Doan ND, Hopewell R, Lubell WDOrganic letters2014

    PMID 2469728610.1021/ol500739k

  2. Growth hormone releasing hexapeptide-6 (GHRP-6) test in the diagnosis of GH-deficiency

    Pombo M, Leal-Cerro A, Barreiro J, et al.Journal of pediatric endocrinology & metabolism : JPEM1996

    PMID 8887178

  3. Growth hormone-releasing peptide 6 (GHRP-6) hydrogel for acute kidney injury therapy via metabolic regulation

    Zhao X, Pan K, Li R, et al.Journal of nanobiotechnology2025

    PMID 4132729010.1186/s12951-025-03888-9

  4. D-Lys3]-GHRP-6 exhibits pro-autophagic effects on skeletal muscle

    Yu AP, Pei XM, Sin TK, et al.Molecular and cellular endocrinology2015

    PMID 2545086210.1016/j.mce.2014.09.031

  5. Growth hormone releasing peptide-6 (GHRP-6) prevents doxorubicin-induced myocardial and extra-myocardial damages by activating prosurvival mechanisms

    Berlanga-Acosta J, Cibrian D, Valiente-Mustelier J, et al.Frontiers in pharmacology2024

    PMID 3887341810.3389/fphar.2024.1402138

  6. Calorie restriction activates a gastric Notch-FOXO1 pathway to expand ghrelin cells

    McKimpson WM, Spiegel S, Mukhanova M, et al.The Journal of cell biology2024

    PMID 3895860610.1083/jcb.202305093

  7. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males

    Sinha DK, Balasubramanian A, Tatem AJ, et al.Translational andrology and urology2020

    PMID 3225785510.21037/tau.2019.11.30

  8. Detection of GHRP-2 and GHRP-6 in urine samples from athletes

    Cox HD, Hughes CM, Eichner DDrug testing and analysis2015

    PMID 2580900010.1002/dta.1791

Collected 2026-08-02from PubMed, phrase-matched on “GHRP-6” in title and abstract. Run the same search.

About GHRP-6

A synthetic hexapeptide, His-D-Trp-Ala-Trp-D-Phe-Lys-NH2, and an agonist at the growth hormone secretagogue receptor type 1a. It differs from GHRP-2 at two positions and was the earlier of the two to be described.

Also known as
SKF-110679

Structure and mechanism only. Nothing above describes what this compound is for, and no dose appears anywhere on this page.

Reading on this compound

All articles

PepRack articles that reference this compound. This is not a news feed — we syndicate nothing and publish no datelines.

Vendor listings are not affiliate links and PepRack earns nothing from them. A listing records a price we observed on a date. It is not a recommendation of a product, dose, or treatment, and PepRack does not verify what any vendor ships.